Trials / Completed
CompletedNCT01569204
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- University of Cologne · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The Purpose of this trial is: * to determine complete response rate (CRR) after six cycles of chemotherapy * to determine complete remission rate (CR/CRr) as final treatment outcome after completion of treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etoposide | |
| DRUG | Cyclophosphamide | |
| DRUG | Doxorubicin | |
| DRUG | Prednisone | |
| DRUG | Procarbazine | |
| DRUG | Dexamethasone | |
| DRUG | Dacarbazine | |
| DRUG | Brentuximab Vedotin |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2014-03-01
- Completion
- 2017-12-01
- First posted
- 2012-04-03
- Last updated
- 2018-10-29
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01569204. Inclusion in this directory is not an endorsement.